Loading... please wait
wolchok 220x220 - Dr. Jedd Wolchok

Dr. Jedd Wolchok

Chief of the Melanoma and Immunotherapeutics Service, Memorial Sloan-Kettering Memorial Cancer Center

Bio Current as of septiembre 15, 2016

Jedd D. Wolchok, MD, PhD Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation Chief, Melanoma & Immunotherapeutics Service Director, Parker Institute for Cancer Immunotherapy at MSK Associate Director, Ludwig Center for Cancer Immunotherapy Member, Ludwig Cancer Research Professor of Medicine, Weill Medical College of Cornell University Memorial Sloan Kettering Cancer Center Dr. Wolchok is the Lloyd J. Old and Daniel K. Ludwig Chair in Clinical Investigation, Chief of the Melanoma and Immunotherapeutics Service, Attending Physician at Memorial Sloan-Kettering Cancer Center (MSK) with an expertise in the treatment of metastatic melanoma. He received his undergraduate degree from Princeton University and both M.D and Ph.D. from New York University, where he also fulfilled his residency program. He completed his fellowship at MSK and remained on faculty with an appointment in the Melanoma and Immunotherapeutics Service, which he now leads. Dr. Wolchok has helped establish MSK as a leader in the discovery and treatment of cancers with novel immunotherapies. Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma and recently designed and led a global phase 3 trial of combined checkpoint blockade for melanoma. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials. In 2011, he established the Immunotherapeutics Clinical Core, a specialized phase 1 outpatient unit at MSK that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification. This group treats patients with a broad spectrum of malignancies and has become a model for similar efforts by other major cancer centers throughout the world.